An examination of a novel multipanel of CSF biomarkers in the Alzheimer’s disease clinical and pathological continuum.

Van, H., E. Jonaitis, T. Betthauser, R. Batrla, N. Wild, G. Kollmorgen, U. Andreasson, O. Okonkwo, B. Bendlin, S. Asthana, C. Carlsson, S. Johnson, H. Zetterberg, and K. Blennow. “An Examination of a Novel Multipanel of CSF Biomarkers in the Alzheimer’s Disease Clinical and Pathological Continuum.”. Alzheimer’s & Dementia : The Journal of the Alzheimer’s Association, 2020.

This study examines the utility of a multipanel of cerebrospinal fluid (CSF) biomarkers complementing Alzheimer’s disease (AD) biomarkers in a clinical research sample. We compared biomarkers across groups defined by clinical diagnosis and pTau181 /Aβ42 status (+/-) and explored their value in predicting cognition.

DOI: 10.1002/alz.12204

PubMed: 33336877